{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:43Z","timestamp":1793642383149,"version":"4.5.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.tranon.2021.101070","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T05:00:39Z","timestamp":1616907639000},"page":"101070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs"],"prefix":"10.1016","volume":"14","author":[{"given":"Ehsan","family":"Moghanloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Mollanoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salar","family":"Pashangzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farimah","family":"Hadjilooei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibollah","family":"Mahmoodzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"179","key":"10.1016\/j.tranon.2021.101070_bib0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/scitranslmed.3005568","article-title":"Cell-based therapeutics: the next pillar of medicine","volume":"5","author":"Fischbach","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2021.101070_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2015.04.010","article-title":"The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy","volume":"128","author":"Khalil","year":"2015","journal-title":"Adv. Cancer Res."},{"issue":"7378","key":"10.1016\/j.tranon.2021.101070_bib0004","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.tranon.2021.101070_bib0006","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.tranon.2021.101070_bib0007","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9967","key":"10.1016\/j.tranon.2021.101070_bib0008","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"224","key":"10.1016\/j.tranon.2021.101070_bib0009","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.tranon.2021.101070_bib0010","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.tranon.2021.101070_bib0011","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"303","key":"10.1016\/j.tranon.2021.101070_bib0012","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.tranon.2021.101070_bib0013","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.tranon.2021.101070_bib0014","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101070_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0016","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.immuni.2016.10.014","article-title":"Targeting of tumor-associated glycoforms of MUC1 with CAR T cells","volume":"45","author":"Maher","year":"2016","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.tranon.2021.101070_bib0017","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0018","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0019","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11427-016-5025-6","article-title":"Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects","volume":"59","author":"Di","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.tranon.2021.101070_bib0022","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0023","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome","volume":"5","author":"Bugelski","year":"2009","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0024","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"issue":"19","key":"10.1016\/j.tranon.2021.101070_bib0025","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.tranon.2021.101070_bib0026","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.tranon.2021.101070_bib0027","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.tranon.2021.101070_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J. Gene Med."},{"issue":"132","key":"10.1016\/j.tranon.2021.101070_bib0031","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","article-title":"A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy","volume":"10","author":"Zhang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2021.101070_bib0033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.tranon.2021.101070_bib0034","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.7150\/thno.41305","article-title":"Synthetic immunity by remote control","volume":"10","author":"Gamboa","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2021.101070_bib0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7150\/jca.2.378","article-title":"Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes","volume":"2","author":"Casucci","year":"2011","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0036","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0037","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2021.101070_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1271857","article-title":"Steering CAR T cells to distinguish friend from foe","volume":"8","author":"Caruso","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tranon.2021.101070_bib0039","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fimmu.2020.00326","article-title":"Emerging approaches for regulation and control of CAR T cells: a mini review","volume":"11","author":"Brandt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2021.101070_bib0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.tranon.2021.101070_bib0041","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0042","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A cetuximab-mediated suicide system in chimeric antigen receptor-modified hematopoietic stem cells for cancer therapy","volume":"30","author":"Kao","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0043","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0044","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.tranon.2021.101070_bib0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"issue":"215","key":"10.1016\/j.tranon.2021.101070_bib0046","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0047","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0048","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"8","key":"10.1016\/j.tranon.2021.101070_bib0049","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J. Am. Chem. Soc."},{"issue":"23","key":"10.1016\/j.tranon.2021.101070_bib0050","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","article-title":"Redirecting gene-modified T cells toward various cancer types using tagged antibodies","volume":"18","author":"Tamada","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6258","key":"10.1016\/j.tranon.2021.101070_bib0051","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0052","doi-asserted-by":"crossref","first-page":"18950","DOI":"10.1038\/srep18950","article-title":"Design of chimeric antigen receptors with integrated controllable transient functions","volume":"6","author":"Juillerat","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2021.101070_bib0053","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0054","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","article-title":"A rapamycin-activated caspase 9-based suicide gene","volume":"26","author":"Stavrou","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tranon.2021.101070_bib0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8922-5_5","article-title":"Generation of suicide gene-modified chimeric antigen receptor-redirected t-cells for cancer immunotherapy","volume":"1895","author":"Minagawa","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"18","key":"10.1016\/j.tranon.2021.101070_bib0056","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101070_bib0057","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-8922-5_2","article-title":"Cancer suicide gene therapy with TK.007","volume":"1895","author":"Hossain","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101070_bib0058","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/10430340050015798","article-title":"Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies","volume":"11","author":"Introna","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.tranon.2021.101070_bib0059","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tranon.2021.101070_bib0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.2019001859","article-title":"A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells","volume":"135","author":"Ruella","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2021.101070_bib0061","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00262-019-02376-y","article-title":"Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells","volume":"68","author":"Koristka","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.tranon.2021.101070_bib0062","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2021.101070_bib0063","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0064","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0066","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0067","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch signaling: an emerging therapeutic target for cancer treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2021.101070_bib0068","first-page":"93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","author":"Huehls","year":"2014","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0069","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(94)90334-4","article-title":"Signal transduction by lymphocyte antigen receptors","volume":"76","author":"Weiss","year":"1994","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.tranon.2021.101070_bib0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-018-0840-y","article-title":"Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy","volume":"17","author":"Pang","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2021.101070_bib0071","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.tranon.2021.101070_bib0072","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:45:37Z","timestamp":1761835537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1936523321000620"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101070","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101070"}}